

**Final Appraisal Recommendation**

Advice No: 1914 – July 2014

**Azithromycin (Zedbac<sup>®</sup>) 500 mg powder for solution for infusion**

**Limited submission by Aspire Pharma Ltd**

**Recommendation of AWMSG**

**Azithromycin (Zedbac<sup>®</sup>) 500 mg powder for solution for infusion is recommended as an option for restricted use within NHS Wales.**

**Azithromycin (Zedbac<sup>®</sup>) 500 mg powder for solution for infusion should be restricted for use within NHS Wales for the treatment of community-acquired pneumonia (CAP) due to susceptible microorganisms, in adult patients where initial intravenous therapy is required.**

**Azithromycin (Zedbac<sup>®</sup>) 500 mg powder for solution for infusion is not recommended for use within NHS Wales for the treatment of pelvic inflammatory disease (PID) due to susceptible microorganisms, in patients where initial intravenous therapy is required.**

**Additional notes:**

- The company submission included evidence for azithromycin (Zedbac<sup>®</sup>) in the treatment of CAP due to susceptible microorganisms, in adult patients where initial intravenous therapy is required. No evidence was provided for azithromycin (Zedbac<sup>®</sup>) in the treatment of PID due to susceptible microorganisms, in patients where initial intravenous therapy is required.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2476), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

Marketing authorisation holder on first issue	Aspire Pharma Ltd
Date of first issue	July 2014
Last reviewed	September 2017

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation –1914: Azithromycin (Zedbac®) 500 mg powder for solution for infusion. Reference number 2476. July 2014